Beam Therapeutics Inc.

Beam Therapeutics Inc. is a U.S.-based biotechnology company focused on base editing, a form of gene editing designed to make precise single-letter DNA changes without cutting both strands of the DNA double helix. The company is building a platform that combines gene editing technologies, delivery capabilities, and internal manufacturing to develop potentially curative therapies for serious diseases. Its lead clinical program is BEAM-101 for sickle cell disease, while much of the rest of the pipeline remains in preclinical or early clinical development. Beam also monetizes its technology through collaboration and license agreements with partners such as Pfizer, Apellis, Orbital Therapeutics, Verve Therapeutics, and Eli Lilly. The business is still in an early commercial stage and currently depends on research collaboration revenue rather than product sales.

−258,6 %

−57,2 %

+120,0 %

13.09

13.09

— Beam Therapeutics Inc.
%
Clinical gene editing programs0% Therapeutic product candidates in preclinical and clinical development, including BEAM-101 for sickle cell disease.
Research collaborations and licenses100% Partnered R&D programs where Beam earns collaboration, option, and license-related revenue.
Base editing platform technology0% Core gene editing intellectual property and enabling technologies used across internal and partnered programs.
Manufacturing services and capabilities0% Internal cGMP manufacturing and process development used to support clinical and future commercial supply.

Beam does not yet sell approved medicines, so its current paying counterparties are collaboration partners rather than...

  • Pharmaceutical collaboration partnersprimary

    Large pharma companies such as Pfizer, Apellis, and Eli Lilly pay for access to Beam's base editing and delivery technologies and may fund downstream development.

  • Biotechnology licensees and co-development partnersprimary

    Specialty biotech firms use Beam's platform in targeted disease programs and may exercise options or share commercialization rights.

  • Future specialty prescribers and treatment centerssecondary

    Hematology and transplant centers would buy and administer Beam's therapies if approved, especially for ex vivo cell therapy products.

  • Payers and reimbursement decision makerssecondary

    Insurers and health systems would determine adoption and access for high-cost genetic medicines, making reimbursement critical to commercialization.

Beam is headquartered in the United States and conducts most of its research, development, and manufacturing activity...

  • •Headquartered in the United States
  • •Research Triangle Park, North Carolina houses its internal cGMP manufacturing facility
  • •Clinical development and regulatory interactions are centered in the U.S.
  • •Collaborations extend to global pharma and biotech partners
  • •Foreign regulatory agencies matter for future trial and approval pathways
  • •No country-level revenue disclosure was provided in the excerpts

Beam's strategy is to build a fully integrated base editing platform that can generate both internal product candidates...

01
Advance BEAM-101 through clinical developmentshort-term

Clinical validation in sickle cell disease is central to proving the platform can deliver durable therapeutic benefit.

02
Deepen partnerships and collaboration revenueshort-term

Partner funding helps support R&D while external validation can de-risk the technology and broaden its reach.

03
Build internal manufacturing and delivery capabilitiesmedium-term

Control over manufacturing and delivery is critical for complex gene-editing medicines and future commercial scalability.

04
Expand the pipeline beyond the lead programmedium-term

A broader portfolio reduces dependence on a single asset and increases the chance of long-term value creation.

Beam faces the core risks of an early-stage biotechnology company: clinical failure, regulatory delay, and the...

high

Clinical development failure

Most programs are still early stage, and the company has not yet proven it can complete pivotal trials or achieve approval.

Scope
BEAM-101 and the broader pipeline
Materiality
high
high

Capital dilution and funding risk

Beam expects continued operating losses and may need to raise additional capital through equity, debt, or partnerships.

Scope
Corporate funding and pipeline execution
Materiality
high
high

Manufacturing and scale-up risk

The company has limited experience producing commercial-scale gene-editing medicines and depends partly on third parties.

Scope
Clinical supply and future commercial supply
Materiality
high
medium

Regulatory disruption

FDA or foreign agency staffing, funding, or process disruptions could delay development and approval timelines.

Scope
U.S. and ex-U.S. regulatory pathways
Materiality
medium
medium

Competitive pressure in gene editing

Other base editing and genetic medicine companies may outpace Beam in technology, partnerships, or clinical progress.

Scope
Platform adoption and partnering
Materiality
medium
Collaboration and license revenue recognition
Can cause significant quarter-to-quarter revenue variability
Fair value measurement of derivative liabilities
Can materially affect reported net loss
Stock-based compensation
Raises operating expense and affects comparability across periods
Lease accounting
Affects balance sheet liabilities and future cash obligations
Accrued and prepaid R&D costs
Can shift reported R&D expense and working capital

Prime Medicine, Inc.

PRME · Biological Products, (No Diagnostic Substances)

Black Diamond Therapeutics, Inc.

BDTX · Biological Products, (No Diagnostic Substances)

CRISPR Therapeutics AG

CRSP · Biological Products, (No Diagnostic Substances)

Caribou Biosciences, Inc.

CRBU · Biological Products, (No Diagnostic Substances)

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Camp4 Therapeutics Corp

CAMP · Pharmaceutical Preparations

: 11/08/2026